Alzamend Neuro (NASDAQ:ALZN) Director Milton Ault III Sells 39,140 Shares

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 39,140 shares of the company’s stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $2.31, for a total transaction of $90,413.40. Following the completion of the sale, the director directly owned 25,882 shares in the company, valued at approximately $59,787.42. This represents a 60.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Alzamend Neuro Stock Down 0.8%

NASDAQ:ALZN opened at $2.36 on Friday. The firm’s fifty day moving average is $2.48 and its 200-day moving average is $4.29. Alzamend Neuro, Inc. has a 52 week low of $2.06 and a 52 week high of $17.10.

Institutional Trading of Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC bought a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned approximately 0.56% of Alzamend Neuro at the end of the most recent reporting period. Institutional investors own 49.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Alzamend Neuro from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Ascendiant Capital Markets dropped their target price on shares of Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Thursday. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $42.00.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.